Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 5/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29747247 | 1.00 | TBXAS1 (0.75) | TBXAS1POLBCHRNB2CHRNA4HRH4 | |
| Hydrochloric Acid SCHEMBL594558 | 0.98 | TBXAS1 (0.73) | TBXAS1POLBCHRNB2CHRNA4HRH4 | |
| SCHEMBL24844947 | 0.86 | TBXAS1 (1.00) | TBXAS1TDP1L3MBTL1 | |
| SCHEMBL10728648 | 0.85 | TBXAS1 (0.56) | TBXAS1CHRNB2CHRNA4HRH4HRH3 | |
| SCHEMBL16067092 | 0.84 | TBXAS1 (0.68) | TBXAS1POLBCHRNB2CHRNA4HRH4 | |
| SCHEMBL3040732 | 0.78 | TBXAS1 (0.50) | TBXAS1CYP1A2TDP1L3MBTL1 | |
| SCHEMBL28772279 | 0.74 | TBXAS1 (0.55) | TBXAS1CHRNB2CHRNA4HRH4HRH3 | |
| SCHEMBL1658826 | 0.73 | FES (0.61) | POLBL3MBTL1 | |
| SCHEMBL727185 | 0.73 | CYP1A2 (0.62) | TBXAS1CHRNB2CHRNA4HRH4HRH3 | |
| SCHEMBL5780182 | 0.69 | ALDH1A1 (0.59) | TBXAS1CHRNB2CHRNA4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 595 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2825208-B1 | P75NTR NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE | LEVICEPT LTD (GB) | 2017-05-17 | — | — | EP | claimed |
| US-20150037335-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2015-02-05 | — | — | US | claimed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | claimed |
| CN-101146539-A | Use of pde7 inhibitors for the treatment of neuropathic pain | PFIZER LTD (GB) | 2008-03-19 | — | — | CN | claimed |
| EP-1855686-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | Pfizer Limited (GB) | 2007-11-21 | — | — | EP | claimed |
| WO-2006092691-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PFIZER LIMITED (GB) | 2006-09-08 | — | — | WO | claimed |
| EP-0234729-B1 | QUINONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1991-12-27 | — | — | EP | claimed |
| JP-8169826-A | — | — | None | — | — | JP | disclosed |
| US-20260146036-A1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC. (JP) | 2026-05-28 | — | — | US | disclosed |
| US-20260139031-A1 | FUSION PROTEIN | LEVICEPT LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4377309-B1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC (JP) | 2026-05-20 | — | — | EP | disclosed |
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SEVENLESS THERAPEUTICS LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| EP-4720104-A1 | LOW AFFINITY P75 NEUROTROPHIC RECEPTOR EXTRACELLULAR DOMAIN FUSED TO A FC MOIETY AS NGF ANTAGONIST THERAPY OF PAIN | Levicept Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| WO-2006011050-A2 | PYRIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2006-02-02 | — | — | WO | disclosed |
| US-6376528-B1 | SYNERGISTIC MIXTURE | G. D. SEARLE & CO. | 2002-04-23 | — | — | US | disclosed |
| US-5563129-A | Hydroquinone derivatives and intermediates for production thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| US-5534639-A | Hydroquinone derivatives and intermediates for production thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-09 | — | — | US | disclosed |
| JP-H08169826-A | PREVENTIVE AND THERAPEUTIC AGENT FOR CACHEXIA | TAKEDA CHEM IND LTD | 1996-07-02 | — | — | JP | disclosed |
| US-5436359-A | Hydroquinone derivatives and intermediates for production thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0560568-A2 | Hydroquinone derivatives and intermediates for production thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146036-A1 | CRYSTALLINE FORMS | PRKCD, CCT8, CRYZ | TBXAS1 3680/4885POLB 639/4885CHRNB2 1226/4885 |
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SOS1, OPRL1, SOS2 | TBXAS1 2683/4885POLB 4752/4885CHRNB2 1090/4885 |
| US-20260139031-A1 | FUSION PROTEIN | NTRK2, BDNF, NGFR | TBXAS1 3549/4885POLB 3524/4885CHRNB2 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.